Iovance Biotherapeutics Attracted a Downgrade. Is It Time to Sell?

Before you make any knee-jerk reactions to Wall Street analyst notes, let's look at what has gone wrong for Iovance and how its situation could improve. In May, Iovance reported more than 40 treatment centers authorized to infuse patients with Amtagvi had enrolled more than 100 patients. Catanzaro downgraded the stock because more than four-fifths of enrolled patients at six treatment centers he surveyed still hadn't received a dose of Amtagvi by the end of June. A slow rollout of Amtagvi shouldn't have cau ...